India’s healthcare system has historically focused more on treating illness than preventing it. Hospitals, insurance coverage and curative interventions have often dominated health policy discussions, while preventive programmes have struggled for sustained attention.
A new nationwide campaign launched in Ajmer by Prime Minister Narendra Modi on February 28, 2026 may represent an important step toward changing that balance. India has begun a national Human Papillomavirus vaccination campaign targeting 14-year-old girls, an initiative aimed at preventing cervical cancer before it develops.
The programme aims to vaccinate roughly 1.15 crore girls each year. Health authorities hope that widespread vaccination during adolescence will reduce future cases of cervical cancer, which remains one of the most common and deadly cancers affecting women in India.
While this initiative alone does not transform India’s health system into a prevention-focused model, it may signal an early but meaningful move toward stronger investment in disease prevention.
The Burden of Cervical Cancer in India
Cervical cancer continues to impose a heavy burden on Indian women and families. According to global health estimates, more than 1.2 lakh women in India are diagnosed with cervical cancer each year and around 80,000 die from the disease. India accounts for a significant share of global cervical cancer deaths.
The disease develops slowly over time and is primarily caused by persistent infection with certain high-risk types of the Human Papillomavirus. HPV is a group of viruses transmitted through skin-to-skin contact. While many infections clear on their own, some strains can persist and eventually lead to cancer.
Two strains in particular, HPV-16 and HPV-18, are responsible for the majority of cervical cancer cases worldwide. Other strains such as HPV-6 and HPV-11 are associated with genital warts but are not typically linked to cancer. Because HPV infection often occurs years before cancer develops, vaccination during adolescence provides an opportunity to prevent the disease before exposure happens.
The Vaccine Being Used in India’s Campaign
The vaccine currently being used in India’s national campaign is Gardasil, specifically the quadrivalent version commonly known as Gardasil-4. The vaccine protects against four HPV strains including 6, 11, 16 and 18.
India’s programme uses the quadrivalent HPV vaccine Gardasil-4, and the doses are being procured through a transparent mechanism in partnership with Gavi, the Vaccine Alliance, to ensure supply reliability and adherence to quality standards.
Gardasil-4 is manufactured by Merck & Co., a global pharmaceutical company that markets the vaccine internationally through its MSD division. HPV vaccines globally have largely been produced by a small number of major manufacturers. Another widely used vaccine, Cervarix, is produced by GlaxoSmithKline.
India has also recently entered the HPV vaccine manufacturing space. Serum Institute of India has developed Cervavac, the country’s first domestically produced HPV vaccine. Cervavac also targets the same four major HPV strains associated with cervical cancer and genital warts.
Although the present national campaign is using Gardasil-4, the emergence of an Indian vaccine manufacturer could expand access and reduce costs in the future. The global HPV vaccine market has historically been dominated by multinational pharmaceutical companies, so the entry of an Indian manufacturer introduces a new dynamic from both public health and business perspectives.
A Global Standard India Is Catching Up To
HPV vaccination has already become part of routine preventive healthcare in many countries. The first HPV vaccines were approved in 2006, and several nations quickly introduced national vaccination programmes.
Countries such as Australia, United Kingdom and New Zealand began vaccinating adolescents through school-based programmes more than a decade ago. These programmes have significantly reduced HPV infections and precancerous cervical lesions among vaccinated populations.
Public health researchers believe that sustained vaccination and screening efforts in some countries could eventually make cervical cancer a rare disease. In comparison, India approved HPV vaccines in 2008 but delayed nationwide implementation for many years due to concerns about cost, logistics and public awareness. The new national campaign therefore represents a delayed but important effort to align India’s preventive health policies with global practice.
Prevention & Economics of Healthcare
HPV vaccination also carries significant economic implications. Cancer treatment often involves surgery, chemotherapy, radiation therapy and long-term follow-up care. These treatments can impose heavy financial burdens on families and public health systems.
Preventive vaccination, by contrast, costs far less than treating advanced cancer. From a healthcare economics perspective, preventing cervical cancer could reduce long-term treatment costs, hospital strain and productivity losses.
This preventive logic has guided several successful public health campaigns in India. Nationwide immunisation efforts helped eliminate wild polio from the country. Large scale vaccination drives against measles and rubella have protected millions of children. Hepatitis-B vaccination has also been incorporated into India’s Universal Immunization Programme.
Each of these campaigns reflects a simple principle. Preventing disease through vaccination can be more effective and more affordable than managing large scale treatment later.
Awareness, Consent & Challenges
Despite the scientific effectiveness of HPV vaccines, the success of the campaign will depend on public awareness and social acceptance. HPV vaccination sometimes faces hesitation in different parts of the world because the virus is transmitted through sexual contact.
In societies where conversations about reproductive health remain sensitive, misinformation and stigma can influence parental decisions. In India, the vaccination programme is voluntary and requires parental consent before adolescents receive the vaccine.
Health authorities are expected to rely on school outreach, community engagement and awareness campaigns to build public trust in the programme. Without clear communication about cervical cancer prevention, even highly effective vaccines may struggle to achieve widespread uptake.
A Step Toward Prevention
Viewed in isolation, the HPV vaccination campaign may appear to be just another immunisation programme. However, it also highlights a broader question about the direction of India’s healthcare system.
For many years, the country’s health infrastructure has been heavily oriented toward curative care, including hospitals and treatment schemes. Preventive care has often received less attention despite its long-term benefits.
The HPV vaccination campaign does not immediately transform that system. However, it may represent an early signal that prevention is receiving greater policy attention. If vaccination coverage remains high, awareness improves and screening programmes expand for adult women, the initiative could significantly reduce the future burden of cervical cancer.
The results of such a programme will take years to become visible because cervical cancer develops slowly. But over time, sustained prevention efforts could help ensure that far fewer women face a disease that is largely preventable today.
The Logical Indian’s Perspective
India’s nationwide HPV vaccination campaign marks an important step toward strengthening preventive healthcare, but its success will depend on sustained awareness, access and public trust. Cervical cancer remains one of the most preventable yet deadly cancers affecting Indian women.
Expanding vaccination, improving screening and addressing social stigma around reproductive health will be crucial to ensuring that preventive initiatives translate into long-term health gains for millions of women.
